Ibrutinib
| CAS No. | 936563-96-1 |
|---|---|
| MDL No. | MFCD20261150 |
| MF | C25H24N6O2 |
| MW | 440.50 |
| InChI Key | XYFPWWZEPKGCCK-GOSISDBHSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Ibrutinib is a (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine derivative with the piperidine nitrogen replaced by an acryloyl group. It is a selective, covalent inhibitor of Bruton's tyrosine kinase, used in the treatment of B-cell malignancies. It functions as an EC 2.7.10.2 non-specific protein-tyrosine kinase inhibitor and an antineoplastic agent. It is classified as a pyrazolopyrimidine, aromatic amine, aromatic ether, acrylamide, N-acylpiperidine, and tertiary carboxamide.
| CAS No. | 936563-96-1 |
|---|---|
| Product Name | Ibrutinib |
Biological Targets
BTK
Associated Conditions
leukemia·marginal zone B-cell lymphoma·Hodgkins lymphoma·mast-cell leukemia·COVID-19·
* The information provided here is compiled from public sources and is for reference only.
